Why PGx?
The trial-and-error method of selecting drug therapies
Failed Therapies
- 2 out of 3 patients fail the first medication prescribed
​
Adverse Drug Reactions
- 4th leading cause of death in the U.S
​
Costs to the Healthcare system
- $530B/yr attributed to non-optimized medication
Genetics are a significant driver in therapy response
Accounts for 20-95% of drug response variability
​
PGx testing reduces ADRs by 52%
​​
Decreases the number of drugs and time to finding an efficacious treatment
Design and
Performance
Comprehensive Test Panel
Test for 77 genetic variants in 21 of the most relevant pharmacogenetic genes
​
Validated on platform optimized for PGx testing
​
Reduce QNS with low DNA input
CYP2D6 CNV and Hybrid Allele Detection
Prevalence​
- 13% of the US population has a CYP2D6 CNV​
- Up to 45% of population has a non-functional hybrid allele
​
PharmGx Assay Design
- Interrogates 7 regions across CYP2D6 and CYP2D7 pseudogene
-
Hybrid allele detection
-
High confidence CYP2D6 CNV detection
Result Interpretation
Clinical decision support for more than 100 medications
​
Supported by drug labels and clinical guidelines
​
Personalized results for every patient
Ease and Convenience
Simple process from ordering to reporting
​
Fast TATs
Patient
Access
Notifications for out-of-pocket estimates > $200
​
Low-cost cash pay and payment plans
​
Financial assistance program
Physician Support
PharmD clinical support on demand
​
Help interpret and advise on results
​
Answer questions about PharmGx testing